MannKind investors panic on Afrezza delay
This article was originally published in Scrip
Executive Summary
Even though it was highly likely the FDA would need more time to make a decision on MannKind's new drug application (NDA) for its experimental inhaled insulin Afrezza (insulin human [rDNA origin]) for type 1 and type 2 diabetes after the agency's panel of outside advisers shocked almost everyone by backing approval of the drug, investors still panicked when regulators did indeed postpone their decision until 15 July.